Clinical validation of the cobas 4800 HPV test for cervical screening purposes

Journal of Clinical Microbiology

Volumn 49, Issue 11, 2011, Pages 3983-3985

  Heideman, D A M ^a   Hesselink, A T ^a   Berkhof, J ^a   Van Kemenade, F ^a   Melchers, W J G ^b   Daalmeijer, N Fransen ^a   Verkuijten, M ^a   Meijer, C J L M ^a   Snijders, P J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VALIDATION STUDY; VIRUS IDENTIFICATION; WART VIRUS;

ADULT; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 80355137211     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05552-11     Document Type: Article

References (8)

1. Castle, P. E., et al. 2009. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 47:3344-3347.
2. Mateos, M. L., A. J. de Chacon, M. Rodriguez-Dominguez, I. Sanz, and M. D. Rubio. 2011. Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening. Enferm. Infecc. Microbiol. Clin. 29:411-414.
3. Meijer, C. J., H. Berkhof, D. A. Heideman, A. T. Hesselink, and P. J. Snijders. 2009. Validation of high-risk HPV tests for primary cervical screening. J. Clin. Virol. 46(Suppl. 3):S1-S4.
4. Meijer, C. J., et al. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
5. Rijkaart, D. C., et al. 2011. Evaluation of 14 triage strategies for HPV DNApositive women in population-based cervical screening. Int. J. Cancer [Epub ahead of print.] doi:10.1002/ijc.26056.
6. Rijkaart, D. C., et al. 2009. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in populationbased cervical screening (VUSA-Screen study). Int. J. Cancer 126:2175-2181.
7. Stoler, M. H., et al. 2011. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol. 135:468-475.
8. van den Brule, A. J., et al. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787.